<DOC>
	<DOCNO>NCT03089645</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , pharmacodynamics antitumor activity adult subject select advance solid tumor malignancy .</brief_summary>
	<brief_title>MEDI5083 Alone Combination With Durvalumab Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description>This global Phase 1 , first-time-in-human , multicenter , open-label , dose-escalation dose-expansion study MEDI5083 alone combination durvalumab .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age â‰¥ 18 year time screen age consent accord local law 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 3 . Histologically cytologically confirm metastatic recurrent tumor type 4 . Subjects receive prior immunotherapy may eligible 5 . Subjects must least one measurable lesion 6 . Consent provide archival tumor tissue pre/ontreatment biopsies 7 . Adequate organ marrow function 8 . Consent use one highly effective method contraception 1 . Receipt systemic anticancer therapy within 28 day prior first dose MEDI5083 2 . Concurrent enrollment another clinical study 3 . Active/prior autoimmune inflammatory disorder 4 . History immunodeficiency , solid organ transplant , tuberculosis 5 . Known allergy/hypersensitivity drug component 6 . Untreated central nervous system ( CNS ) metastatic disease , leptomeningeal disease , cord compression 7 . Current prior use immunosuppressive medication within 14 day prior first dose MEDI5083</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>